JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5001
Nuvation Bio
NUVB
$1.67B
| $149K | ﹤0.01% |
89,930
+23,258
| +35% | +$47.1K |
2021 Q2
7 quarters
|
|
5002
Tucows
TCX
$102M
| $149K | ﹤0.01% |
7,646
+1,604
| +27% | +$46.3K |
2017 Q4
21 quarters
|
|
|
KNTE
5003
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $149K | ﹤0.01% |
23,880
+5,962
| +33% | +$36.3K |
2021 Q1
8 quarters
|
|
5004
Future Fuel
FF
$224M
| $148K | ﹤0.01% |
20,122
+5,352
| +36% | +$46K |
2013 Q2
39 quarters
|
|
5005
Nuveen Quality Municipal Income Fund
NAD
$2.35B
| $148K | ﹤0.01% |
+12,838
| New | +$149K |
2023 Q1
0 quarters
|
|
|
NEXN
5006
Nexxen International
NEXN
$497M
| $148K | ﹤0.01% |
28,245
+27,885
| +7,746% | +$196K |
2021 Q2
7 quarters
|
|
5007
Village Super Market
VLGEA
$651M
| $148K | ﹤0.01% |
6,486
-1,725
| -21% | -$39.5K |
2015 Q2
31 quarters
|
|
5008
Schwab Fundamental US Large Company Index ETF
FNDX
$27.5B
| $147K | ﹤0.01% |
8,088
+1,698
| +27% | +$31.2K |
2018 Q3
18 quarters
|
|
5009
BCB Bancorp
BCBP
$261M
| $147K | ﹤0.01% |
11,169
-3,422
| -23% | -$56.8K |
2017 Q4
21 quarters
|
|
|
SRTA
5010
Strata Critical Medical Inc
SRTA
$421M
| $147K | ﹤0.01% |
43,573
+10,326
| +31% | +$42.1K |
2022 Q1
4 quarters
|
|
|
HPS
5011
John Hancock Preferred Income Fund III
HPS
$379M
| $147K | ﹤0.01% |
+10,060
| New | +$150K |
2023 Q1
0 quarters
|
|
5012
Playboy Inc
PLBY
$123M
| $147K | ﹤0.01% |
74,323
-7,811
| -10% | -$19.4K |
2021 Q2
7 quarters
|
|
5013
James Hardie Industries
JHX
$14.8B
| $147K | ﹤0.01% |
6,829
-5,079
| -43% | -$108K |
2015 Q1
32 quarters
|
|
5014
PUT
Aclaris Therapeutics
ACRS
$578M
| $146K | ﹤0.01% |
+18,000
| New | +$228K |
2023 Q1
0 quarters
|
|
5015
Equinox Gold
EQX
$13B
| $146K | ﹤0.01% |
+28,395
| New | +$118K |
2023 Q1
0 quarters
|
|
5016
Fossil Group
FOSL
$426M
| $145K | ﹤0.01% |
45,007
+4,737
| +12% | +$21.3K |
2013 Q2
39 quarters
|
|
5017
Mineralys Therapeutics
MLYS
$1.99B
| $145K | ﹤0.01% |
+9,269
| New | +$156K |
2023 Q1
0 quarters
|
|
5018
Blend Labs
BLND
$244M
| $144K | ﹤0.01% |
145,296
+34,435
| +31% | +$52.8K |
2021 Q3
6 quarters
|
|
5019
CALL
NovoCure
NVCR
$1.81B
| $144K | ﹤0.01% |
2,400
-38,900
| -94% | -$3.11M |
2022 Q1
4 quarters
|
|
|
GOEV
5020
DELISTED
Canoo Inc. Class A Common Stock
GOEV
| $144K | ﹤0.01% |
479
+267
| +126% | +$113K |
2021 Q2
7 quarters
|
|
5021
Smartbird Inc
BIRD
$37.6M
| $143K | ﹤0.01% |
5,969
+113
| +2% | +$5.21K |
2021 Q4
5 quarters
|
|
|
JBIO
5022
Jade Biosciences
JBIO
$857M
| $143K | ﹤0.01% |
202
+52
| +35% | +$43.1K |
2021 Q3
6 quarters
|
|
5023
KFA Mount Lucas Managed Futures Index Strategy ETF
KMLM
$563M
| $143K | ﹤0.01% |
4,853
+4,654
| +2,339% | +$139K |
2022 Q4
1 quarter
|
|
5024
Nuveen Preferred & Income Opportunities Fund
JPC
$2.48B
| $141K | ﹤0.01% |
21,424
+19,311
| +914% | +$141K |
2022 Q4
1 quarter
|
|
5025
Pure Cycle
PCYO
$263M
| $141K | ﹤0.01% |
14,917
+3,834
| +35% | +$35.3K |
2017 Q4
21 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.